Lymphoma

FDA orders new info warnings on CAR-T therapies
By LabPulse.com staff writers
Following its review of reports of T-cell malignancies associated with the administration of six CAR-T immunotherapies, the FDA has instructed the manufacturers to include warnings in the prescribing info for the therapeutics.
January 30, 2024
Fda Button Social
Next-generation sequencing can help diagnose T-cell lymphoma
By Leah Sherwood
"We suggest a testing strategy using t-NGS as the primary test, followed by TCR [T-cell receptor] clonality analysis if negative," wrote the authors, led by Charlotte Syrykh of the pathology department at the Cancer University Institute of Toulouse-Oncopole in Toulouse, France.
November 18, 2021
2020 01 16 22 39 3973 Dna Sequencing Genome 400
Fosun Kite announces CAR T-cell therapy approval
By LabPulse.com staff writers
The therapy is for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
June 24, 2021
2019 10 09 17 32 0093 Dna Cancer Cell 400
CAP, ASCP release lymphoma workup guide
By LabPulse.com staff writers
The guidelines focus on lymphoma diagnosis using samples from fine-needle aspirations or needle biopsies, and the increasing need to perform additional tests to identify lymphoma subtypes.
November 11, 2020
2020 11 12 22 09 6428 Scientists Pharmaceutical Laboratory 400
Roche wins FDA nod for follicular lymphoma mutation test
By LabPulse.com staff writers
A companion diagnostic for patients with follicular lymphoma, Roche's new cobas test detects mutations in the EZH2 gene in follicular lymphoma patients who may be eligible for treatment with the drug tazemetostat (Epizyme's Tazverik), which acts as a selective EZH2 gene inhibitor.
June 22, 2020
2019 05 02 23 38 2538 Check Mark 400
AbbVie to deploy Adaptive's clonoSeq test in myeloma trials
By LabPulse.com staff writers
Venclexta is currently approved by the U.S. Food and Drug Administration (FDA) for use in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, and in older patients with newly diagnosed acute myeloid leukemia who can't tolerate intensive chemotherapy. It is being tested for a number of additional indications, including multiple myeloma.
December 8, 2019
2019 12 09 20 32 9244 Multiple Myeloma 400
Page 1 of 1